|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These values were compared with clinical parameters including SUV<sub>m</sub>, maximum tumor diameter (TD), stage, grade, and MIB1/Ki67 proliferation index.
|
31846640 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Edema diameter and the proliferation marker MIB-1 were negatively associated with the incidence and intensity of preoperative headache, while the content of prostaglandin E<sub>2</sub> in the tumor tissue was positively associated with preoperative headache intensity.
|
30089403 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Instead, cyclooxygenase 2 expression increases with tumor extension while MIB1 expression is not associated with tumor size.
|
31291992 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It underscores the similarities between the baseline cyto-morphology and benign mimics (low-grade squamous intraepithelial lesions), the subtle cytologic and immunohistochemical (MIB1) features heralding biologic aggressiveness, and in some potential pathways (p53) not usually involved in HPV-related anogenital neoplasia.
|
30312218 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MIB1/Ki67 highlighted 2% to 3% tumor nuclei (low).Diagnosis of a SFT was rendered.
|
29257041 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor specimens were examined histologically using the current WHO 2016 classification and immunohistochemically using Ki-67/MIB-1 monoclonal antibody.
|
28350689 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the knockdown of GJB‑2 led to a significant reduction in tumor volume and proliferation (as demonstrated by MIB‑1 staining) in orthotopic xenografts in immunocompromised mice.
|
30542725 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MIB index ≥3.5% is associated with recurrence in VS. Maximal diameter of the tumor and extent of resection are perhaps not associated with recurrence of VS.
|
30240870 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients harboring tumors ≥ 3 cm were significantly older (56.9 ± 15.2 years vs 53.1 ± 13.6 years; p = 0.07), more frequently male (40.8% vs 14.6%; p = 0.0001), and had greater EBL (446.5 ± 532.2 ml vs 185.4 ± 197.2 ml; p = 0.0001), greater tumor volume (33.9 ± 38.1 ml vs 29.4 ± 23.5 ml; p = 0.0001), higher MIB-1 index values (3.0% ± 5.4% vs 1.7% ± 1.7%; p = 0.03), higher vWF levels (85.6% ± 76.9% vs 54.1% ± 52.4%; p = 0.001), lower HIF-1 expression (1.4 ± 1.3 vs 2.2 ± 1.4; p = 0.004), and worse OS (199.9 ± 7.6 months vs 180.8 ± 8.1 months; p = 0.05) than patients with tumors < 3 cm.
|
28362240 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No single feature reliably identified high RS patients; however, a model accounting for age, HR expression, proliferative index (MIB1/Ki67), histology, and tumor size was generated, with receiver operator area under the curve 0.909.
|
29679201 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mitotic index (MI), Ki-67/MiB-1 positivity percentage and PTTG expression were analyzed in correlation to each other as well as to the tumor WHO grades.
|
29575197 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The acute effects of ASA404 on tumor tissue were analyzed using conventional and immunohistochemical staining techniques [hematoxylin and eosin, MIB-1 antibody/proliferation maker protein Ki-67, cleaved caspase-8, stimulator of interferon genes (STING), ionized calcium-binding adapter molecule 1].
|
29098034 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, the degree of resection and tumor immunoreactivity to MIB-1 (i.e., Ki-67 labeling index (LI)) are described in recurrent and non-recurrent meningioma cases.
|
29312841 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results showed that there were statistical associations between Ki-67/MIB-1 and age (odds ratio [OR] =1.71, 95% CI: 1.14-2.57, <i>P</i>=0.010), tumor size (OR =1.86, 95% CI: 1.17-2.96, <i>P</i>=0.008), lymph node metastasis (OR =2.49, 95% CI: 1.42-4.39, <i>P</i>=0.002), metastasis status (OR =6.96, 95% CI: 2.46-19.69, <i>P</i><0.001), tumor node metastasis stage (OR =6.56, 95% CI: 3.80-11.34, <i>P</i><0.001) and extrathyroid extension (OR =1.91, 95% CI: 1.27-2.87, <i>P</i>=0.002).
|
28740401 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Univariate analysis revealed a statistically significant association between 5-ALA fluorescence and the isocitrate dehydrogenase 1 (IDH1) status, 1p19q loss of heterozygosity (LOH), the MIB-1 labeling index, and the tumor margin, -heterogeneity, and -contrast enhancement on MRI scans (p < 0.001, p = 0.003, p = 0.007, p = 0.046, p = 0.021, and p = 0.002, respectively).
|
28740449 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the hetero/hetero group, the tumor size was significantly greater and the MIB-1 index was significantly higher (both P < 0.05), than the other two groups.
|
27306258 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Upon this, we established a new score using mitosis, necrosis, size of the tumor and MIB-1, which performed better than the traditional scores in our data set.
|
29246159 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The area occupied by vessels was also markedly increased in AO vs WDO, as was the microvessel density.Proliferating endothelial cells i.e. those with MIB-1 positive nuclei in CD34 positive cells were significantly increased (4.6 vs 0.26 positive nuclei per unit tumor area, P≤0.001) in AO.
|
28469969 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ancillary stains including p16, p53, MIB-1, trichrome, and reticulin may be helpful in tumors harboring necrosis that is difficult to classify.
|
28353387 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Somatic mutations and gene amplification were found only in BRCA1/2 mutation negative MBCs.Significant associations emerged between EGFR amplification and large tumor size (T4), ER-negative and HER2-positive status, between CCND1 amplification and HER2-positive and MIB1-positive status, and between ESR1 deletion and ER-negative status.Our results show that amplification of targetable oncogenes is frequent in BRCA1/2 mutation negative MBCs and may identify MBC subsets characterized by aggressive phenotype that may benefit from potential targeted therapeutic approaches.
|
27765917 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry for tumor expression of CXCL12 was assessed as a biomarker of relapse alongside vascular invasion, histology (percentage embryonal carcinoma), and MIB1 staining for proliferation in formalin-fixed paraffin-embedded orchidectomy samples from patients enrolled in the Medical Research Council's TE08/22 prospective trials of surveillance in stage I NSGCTs.
|
26453693 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On univariate analysis, we found several statistically significant associations (p < 0.05) including adenoma size with age, sex and tumor protein p53 reactivity; cavernous sinus invasion with size, non-functional status, increased mitotic activity, an elevated MIB-1 proliferation index and p53 reactivity; suprasellar/subfrontal extension with p53 reactivity; and infrasellar invasion with age and tumor size.
|
25979255 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hence, the present study was conducted to evaluate EZH2 expression in astrocytic and oligodendroglial tumors and correlate with CDKN2A/p16 status as well as MIB-1 labeling index (LI).
|
26096306 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
After 30 day TQ and/or cisplatin treatment, we measured the following indices: tumor burden (ascites volume, number of peritoneal implants and mesenteric tumor mass); NF-κB reporter activity (luciferase assay); protein expression of the double-strand DNA break marker, pH2AX(ser139), the proliferation markers, Ki67/mib-1 and PCNA, and the apoptosis markers, cleaved caspase-3, cleaved PARP and Bax; and mRNA expression of NF-κB targets, TNF-α and IL-1β.
|
26215403 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry staining revealed that the tumor cells were positive for Leu-M1, HBME-1, 34βE12, and MIB-1 labeling index was low.
|
26191315 |
2015 |